Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction

Cancers

Rakhshanda Layeequr Rahman¹ 

[1] Division of Surgical Oncology, Texas Tech University Health Sciences Center, Amarillo Breast Center of Excellence, 1400 Coulter, Amarillo, TX 79106, USA

关键词: aromatase inhibitors;    chemoprevention;    exemestane;    raloxifene;    SERMs;    tamoxifen;   

DOI  :  10.3390/cancers4041146

来源: mdpi

【 摘 要 】

Women who are at high risk of breast cancer can be offered chemoprevention. Chemoprevention strategies have expanded over the past decade and include selective receptor modulator inhibitors and aromatase inhibitors. Physicians are expected to provide individualized risk assessments to identify high risk women who may be eligible for chemoprevention. It is prudent that physicians utilize a shared decision approach when counseling high risk women about their preventive options. Barriers and misperceptions however exist with patient and physician acceptance of chemoprevention and continue to impede uptake of chemoprevention as a strategy to reduce breast cancer risk. Programs to increase awareness and elucidate the barriers are critical for women to engage in cancer prevention and promote chemoprevention adherence.

【 授权许可】

CC BY   
© 2012 by the authors; licensee MDPI, Basel, Switzerland.